{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:02:49Z","timestamp":1789758169267,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,9]]},"DOI":"10.7759\/cureus.40171","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T11:30:47Z","timestamp":1686310247000},"source":"Crossref","is-referenced-by-count":4,"title":["Durvalumab-Associated Myocarditis Initially Presenting With Sinus Bradycardia Progressing Into Complete Heart Block"],"prefix":"10.7759","author":[{"given":"Suhwoo","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vaysblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Beccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Makaryus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S162214","article-title":"Safety and efficacy of durvalumab (MEDI4736) in various solid tumors","volume":"12","author":"Yang H","year":"2018","unstructured":"Yang H, Shen K, Zhu C, Li Q, Zhao Y, Ma X. Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. Drug Des Devel Ther. 2018, 12:2085-96. 10.2147\/DDDT.S162214","journal-title":"Drug Des Devel Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon AR","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018, 19:e447-58. 10.1016\/S1470-2045(18)30457-1","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier M","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al.. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017, 136:2085-7. 10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5438","article-title":"Arrhythmic events associated with immune checkpoint inhibitors therapy: a real-world study based on the Food and Drug Administration Adverse Event Reporting System database","volume":"12","author":"Liu Y","year":"2023","unstructured":"Liu Y, Chen Y, Zeng Z, Liu A. Arrhythmic events associated with immune checkpoint inhibitors therapy: a real-world study based on the Food and Drug Administration Adverse Event Reporting System database. Cancer Med. 2023, 12:6637-48. 10.1002\/cam4.5438","journal-title":"Cancer Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9070203","article-title":"ICIs-related cardiotoxicity in different types of cancer","volume":"9","author":"Dong M","year":"2022","unstructured":"Dong M, Yu T, Zhang Z, et al.. ICIs-related cardiotoxicity in different types of cancer. J Cardiovasc Dev Dis. 2022, 9:10.3390\/jcdd9070203","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2018.05.014","article-title":"Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report","volume":"25","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Chen CL, Shapnik N, Krishnan U, Singh HS, Makker V. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report. Gynecol Oncol Rep. 2018, 25:74-7. 10.1016\/j.gore.2018.05.014","journal-title":"Gynecol Oncol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7644-21","article-title":"Durvalumab-associated late-onset myocarditis successfully treated with corticosteroid therapy","volume":"61","author":"Maetani T","year":"2022","unstructured":"Maetani T, Hamaguchi T, Nishimura T, Marumo S, Fukui M. Durvalumab-associated late-onset myocarditis successfully treated with corticosteroid therapy. Intern Med. 2022, 61:527-31. 10.2169\/internalmedicine.7644-21","journal-title":"Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang L","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, et al.. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020, 141:2031-4. 10.1161\/CIRCULATIONAHA.119.044703","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1515\/med-2022-0611","article-title":"Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block","volume":"17","author":"Hu C","year":"2022","unstructured":"Hu C, Zhao L, Zhou C, et al.. Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block. Open Med (Wars). 2022, 17:2109-16. 10.1515\/med-2022-0611","journal-title":"Open Med (Wars)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/150325-durvalumab-associated-myocarditis-initially-presenting-with-sinus-bradycardia-progressing-into-complete-heart-block","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:53Z","timestamp":1707508853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/150325-durvalumab-associated-myocarditis-initially-presenting-with-sinus-bradycardia-progressing-into-complete-heart-block"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.40171","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}